Opinion|Videos|February 6, 2025
Insights From SABCS 2024 and Future Directions in Breast Cancer
Author(s)Katherine Clifton, MD, Shipra Gandhi, MD
Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When considering these SERD trials, emerging data with ADCs, and other targeted therapies (eg, inavolisib), how are you approaching clinical decision-making and sequencing in your patients?
- How do you anticipate sequencing SERDs in patients who may have received multiple prior lines of endocrine-based therapy?
- How do you envision optimally sequencing SERDs, ADCs, and other treatment options? How would you balance considerations about efficacy, safety, mechanism of action, and patient characteristics when determining the optimal treatment sequence?
- Please highlight the most exciting data or studies from SABCS that you find most promising in terms of improving outcomes in HR+/HER2– mBC.
- How has precision medicine improved outcomes and the patient experience from your perspective?
Advertisement
Related to this article
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.
Advertisement
Advertisement
Trending on OncLive
1
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
2
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
3
Dive Into Key Data and Presentations From EHA 2026
4
Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML
5